Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.46 |
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.43 |
| ▸ | CTSK | P43235 | 2/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17577036 | 0.87 | PLA2G10 (0.55) | CA1CA2CA7CAPN1AAK1 | |
| SCHEMBL28175055 | 0.85 | CTSK (0.45) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL2727644 | 0.85 | CA2 (0.43) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL211543 | 0.85 | CA2 (0.43) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL211542 | 0.85 | CA2 (0.43) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL9606612 | 0.85 | CTSK (0.45) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL7444041 | 0.84 | TDP1 (0.49) | CA1CA2CA7CAPN1AAK1 | |
| SCHEMBL28467190 | 0.83 | TSHR (0.46) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL24387611 | 0.82 | CA1 (0.49) | CA1CA2CA7CAPN1AAK1 | |
| SCHEMBL20064066 | 0.81 | CTSK (0.44) | CA1CA2CA7CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12486231-B2 | Targeted nitroxide compounds and their use in treating ferroptosis-related diseases | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-12-02 | — | — | US | disclosed |
| US-20220259149-A1 | Targeted Nitroxide Compounds and Their Use in Treating Ferroptosis-Related Diseases | DEFENSE THREAT REDUCTION AGENCY, US DOD | 2022-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12486231-B2 | Targeted nitroxide compounds and their use in treating ferroptosis-related diseases | HMOX1, AIFM2, HMOX2 | CA1 2936/4885CA2 3508/4885CA7 4164/4885 |
| US-20220259149-A1 | Targeted Nitroxide Compounds and Their Use in Treating Ferroptosis-Related Diseases | HMOX1, AIFM2, HMOX2 | CA1 2936/4885CA2 3508/4885CA7 4164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.